These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1889348)

  • 1. Use of human ultralente as the basal insulin component in treatment of patients with IDDM.
    Freeman SL; O'Brien PC; Rizza RA
    Diabetes Res Clin Pract; 1991 Jul; 12(3):187-92. PubMed ID: 1889348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of beef ultralente for basal insulin delivery: plasma insulin concentrations after chronic ultralente administration in patients with IDDM.
    Rizza RA; O'Brien PC; Service FJ
    Diabetes Care; 1986; 9(2):120-3. PubMed ID: 3698778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of human ultralente is limited by great intraindividual variability in overnight plasma insulin profiles.
    Lindström T; Olsson PO; Arnqvist HJ
    Scand J Clin Lab Invest; 2000 Aug; 60(5):341-7. PubMed ID: 11003253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of basal hepatic glucose production and fasting hyperglycemia of type I diabetic patients treated with human recombinant ultralente insulin.
    Riccio A; Avogaro A; Valerio A; Zappella A; Tiengo A; Del Prato S
    Diabetes Care; 1994 Jun; 17(6):535-40. PubMed ID: 8082521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of human ultralente- and lente-based twice-daily injection regimens.
    Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I
    Diabet Med; 1989 Aug; 6(6):496-501. PubMed ID: 2527130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The subcutaneous absorption of human and bovine ultralente insulin formulations.
    Hildebrandt P; Berger A; Vølund A; Kühl C
    Diabet Med; 1985 Sep; 2(5):355-9. PubMed ID: 2951089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
    Burge MR; Waters DL; Holcombe JH; Schade DS
    J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early morning glycaemia and the metabolic consequences of delaying breakfast/morning insulin. A comparison of continuous subcutaneous insulin infusion and multiple injection therapy with human isophane or human ultralente insulin at bedtime in insulin-dependent diabetics.
    Haakens K; Hanssen KF; Dahl-Jørgensen K; Vaaler S; Torjesen P; Try K
    Scand J Clin Lab Invest; 1989 Nov; 49(7):653-9. PubMed ID: 2692136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro).
    Rabasa-Lhoret R; Bourque J; Ducros F; Chiasson JL
    Diabetes Care; 2001 Apr; 24(4):625-30. PubMed ID: 11315820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term use of intramuscular insulin therapy in a type I diabetic patient with subcutaneous insulin resistance.
    Brossard JH; Havrankova J; Rioux D; Bertrand S; D'Amour P
    Diabet Med; 1993 Mar; 10(2):174-6. PubMed ID: 8458196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human ultralente insulin.
    Holman RR; Steemson J; Darling P; Reeves WG; Turner RC
    Br Med J (Clin Res Ed); 1984 Mar; 288(6418):665-8. PubMed ID: 6421424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human ultralente insulin: a comparison with porcine lente insulin as a twice-daily insulin in insulin-dependent diabetic patients with fasting hyperglycaemia.
    Francis AJ; Hanning I; Alberti KG
    Diabetes Res; 1986 Jun; 3(5):263-8. PubMed ID: 3527523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of meal carbohydrate content on insulin requirements in type 1 diabetic patients treated intensively with the basal-bolus (ultralente-regular) insulin regimen.
    Rabasa-Lhoret R; Garon J; Langelier H; Poisson D; Chiasson JL
    Diabetes Care; 1999 May; 22(5):667-73. PubMed ID: 10332663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the safety and effectiveness of human and bovine long-acting insulins.
    Selam JL; Turner D; Woertz L; Eichner HL; Lauritano A; Charles MA
    Diabetes Res; 1989 Nov; 12(3):131-4. PubMed ID: 2635094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of insulin-dependent diabetes using an injection pen: control, problems and patient preferences.
    Fisken RA; Goulbourn J
    Diabetes Res; 1989 Aug; 11(4):195-7. PubMed ID: 2696619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultralente insulin treatment of transient neonatal diabetes mellitus.
    Mitamura R; Kimura H; Murakami Y; Nagaya K; Makita Y; Okuno A
    J Pediatr; 1996 Feb; 128(2):268-70. PubMed ID: 8636827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal administration of lispro insulin in hyperglycemic type 1 diabetes.
    Rassam AG; Zeise TM; Burge MR; Schade DS
    Diabetes Care; 1999 Jan; 22(1):133-6. PubMed ID: 10333914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes.
    Kudva YC; Basu A; Jenkins GD; Pons GM; Quandt LL; Gebel JA; Vogelsang DA; Smith SA; Rizza RA; Isley WL
    Diabetes Care; 2005 Jan; 28(1):10-4. PubMed ID: 15616226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mixing insulin lispro and ultralente insulin.
    Bastyr EJ; Holcombe JH; Anderson JH; Clore JN
    Diabetes Care; 1997 Jun; 20(6):1047-8. PubMed ID: 9167130
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.